免疫組織化学 (IHC) 市場 – 2029年までの世界予測

Report Overview

The global immunohistochemistry market is projected to reach USD 5.2 billion by 2029 from USD 3.7 billion in 2024, at a CAGR of 7.2% during the forecast period of 2024 to 2029.

世界の免疫組織化学 (IHC) 市場は、2024年から2029年の予測期間中に7.2%のCAGRで、2024年の37億米ドルから2029年までに52億米ドルに達すると予測されています。

Factors propelling the growth of the market are the increased prevalence of cancer cases among the growing geriatric population and the rising application of IHC tests for the diagnosis and management of cancer. Moreover, the development of companion diagnostics (CDx) and its integration with IHC technology for the development of personalized medicine further support the expansion of the market. Application of IHC in supporting drug development and disease management to improve patient outcomes, along with ongoing research collaboration between pharmaceutical companies and academic institutes provide growth opportunities for players in the Immunohistochemistry Market.

“Histological Stain is expected to account for the largest share of by reagents segment.”

In 2023, the histological stains market accounted for the largest share of the reagent subsegment within the product segment. In immunohistochemistry, histological stains are used to visualize and differentiate specific cellular components and structures within tissue samples. Histological stains are also used in multiplex staining also known as multiple staining. In this technique, more than one stains are used to detect multiple targets within a single tissue section. Apart from multiplex staining, histological stains are also used for cancer diagnosis by distinguishing normal and abnormal tissue morphology. These applications are major factors that drive the market for histological stains

“Research applications segment accounted for the second-largest share of the application segment.”

In 2023, research applications accounted for the second-largest share of the application segment of the IHC market. In research, IHC technology is used for anti-tumor drug development and biomarker discovery. It helps researchers to identify the expression of specific proteins and their locations within cells, aiding in the study of cancer and other diseases. For example, IHC is widely used to study the cancer proteome, which helps in finding new drug targets. Automated IHC platforms used in research offer consistent staining across slides, which is essential for reliable results. IHC techniques are also important in developmental studies, like embryological research, where they help visualize key proteins during the embryonic development phase. In stem cell research, IHC is used to monitor differentiation and proliferation markers, providing insights into stem cell behavior. Additionally, in drug testing, IHC helps evaluate the effects of new drugs on specific protein expressions within tissues. These applications highlight the important role of IHC in advancing scientific research and improving the understanding and treatment of various diseases.

“Asia Pacific is the fastest-growing region in the immunohistochemistry market.”

The immunohistochemistry market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM), the Middle East, and Africa. Asia Pacific is the fastest-growing region in terms of CARG during the forecast period. The high growth rate of the region can be attributed to the fast adoption of the latest technologies such as advanced IHC products (like assays and diagnostic kits) in research and clinical applications. This factor, coupled with the increasing geriatric population, rising investments and funding for research activities, increasing disposable income, and developing academic and healthcare infrastructures in the region are key drivers for the high growth rate of the region.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers – 55%, CXOs – 20%, and Executives – 25%
• By Region: North America -50%, Europe -20%, Asia-Pacific -20%, Latin America- 7%, Middle East and Africa-3%

Prominent Players in the Immunohistochemistry market are F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US).

Research Coverage:

This report provides a detailed picture of the immunohistochemistry market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall immunohistochemistry market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (Rising Geriatric Population and Increasing Cancer Prevalence, Innovations and advancements in Immunohistochemistry (IHC) Technology, Reimbursement Coverage for Immunohistochemistry (IHC) Tests, Rising Adoption of Digital Pathology), restraint (Adoption of alternative technologies and a high degree of consolidation), opportunities (Rising demand for personalized medicine, Growing adoption of companion diagnostics, Growth opportunities in emerging countries, Integration of artificial intelligence in IHC), Challenges (Stringent regulatory requirements, Lack of Standardization)
• Product Development/Innovation: Detailed insights on newly launched product, and technological assessment of the Immunohistochemistry market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the Immunohistochemistry market across varied regions.
• Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the Immunohistochemistry market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffman-La Roche Ltd (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US) among others in the Immunohistochemistry market. The report also helps stakeholders understand the pulse of the IHC market and provides them with information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 analogues market.

Table of Contents

1               INTRODUCTION        45

1.1            STUDY OBJECTIVES 45

1.2            MARKET DEFINITION                45

1.3            INCLUSIONS AND EXCLUSIONS               46

1.4            STUDY SCOPE          47

1.4.1        SEGMENTS COVERED              47

1.4.2        YEARS CONSIDERED                48

1.4.3        CURRENCY CONSIDERED        48

1.5            STAKEHOLDERS      48

1.6            SUMMARY OF CHANGES         49

2               RESEARCH METHODOLOGY    50

2.1            RESEARCH DATA     50

2.1.1        RESEARCH DESIGN 50

2.1.2        SECONDARY DATA   51

2.1.2.1     Secondary data sources          51

2.1.2.2     Objectives of secondary research           51

2.1.3        PRIMARY DATA         52

2.1.3.1     Objectives of primary research                52

2.2            MARKET SIZE ESTIMATION      53

2.2.1        REVENUE SHARE ANALYSIS (TOP-DOWN APPROACH)             54

2.2.2        INSIGHTS FROM PRIMARIES   55

2.3            MARKET GROWTH FORECAST 56

2.4            DATA TRIANGULATION              58

2.5            STUDY ASSUMPTIONS             58

2.6            RESEARCH LIMITATIONS         59

2.7            RISK ANALYSIS        59

3               EXECUTIVE SUMMARY             60

4               PREMIUM INSIGHTS                 63

4.1            IMMUNOHISTOCHEMISTRY MARKET OVERVIEW    63

4.2            NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION AND

COUNTRY (2023)     64

4.3            IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)                  64

4.4            IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2023   65

4.5            IMMUNOHISTOCHEMISTRY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES    65

5               MARKET OVERVIEW 66

5.1            INTRODUCTION        66

5.2            MARKET DYNAMICS                 66

5.2.1        DRIVERS  67

5.2.1.1     Increasing prevalence of cancer and rising geriatric population             67

5.2.1.2     Technological innovations and advancements in immunohistochemistry diagnostics                  70

5.2.1.3     Favorable reimbursement coverage for immunohistochemistry tests   71

5.2.1.4     Growing focus on digital pathology          72

5.2.2        RESTRAINTS             73

5.2.2.1     Adoption of alternative technologies in molecular diagnostics and research        73

5.2.2.2     Highly consolidated market    74

5.2.3        OPPORTUNITIES      75

5.2.3.1     Growing demand for precision/personalized medicines        75

5.2.3.2     Increasing adoption of companion diagnostics      76

5.2.3.3     Growth opportunities in emerging economies        76

5.2.3.4     Integration of AI in immunohistochemistry              77

5.2.4        CHALLENGES           77

5.2.4.1     Stringent regulatory requirements for tissue diagnostic instruments and consumables                  77

5.2.4.2     Lack of standardization           77

5.3            TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS                78

5.4            PRICING ANALYSIS  78

5.4.1        AVERAGE SELLING PRICE OF IMMUNOHISTOCHEMISTRY PRODUCTS, 2023        79

5.4.2        INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2021–2023        80

5.4.3        INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, BY REGION, 2021–2023              80

5.5            TECHNOLOGY ANALYSIS          82

5.5.1        KEY TECHNOLOGIES                83

5.5.1.1     Automated immunohistochemistry systems           83

5.5.1.2     Multiplex immunohistochemistry            83

5.5.2        COMPLEMENTARY TECHNOLOGIES        83

5.5.2.1     Chromogenic detection           83

5.5.2.2     Fluorescent detection              84

5.5.3        ADJACENT TECHNOLOGIES     84

5.5.3.1     In situ hybridization 84

5.6            PATENT ANALYSIS   85

5.6.1        METHODOLOGY       85

5.6.2        INNOVATION AND PATENT APPLICATIONS               85

5.6.3        TOP PATENT APPLICANTS        85

5.7            VALUE CHAIN ANALYSIS           88

5.7.1        RESEARCH & DEVELOPMENT 89

5.7.2        MANUFACTURING    89

5.7.3        LOGISTICS AND POST-SALES  89

5.8            SUPPLY CHAIN ANALYSIS        89

5.9            ECOSYSTEM ANALYSIS            90

5.9.1        ROLE OF RAW MATERIAL SUPPLIERS     91

5.9.2        ROLE OF PRODUCT PROVIDERS               92

5.9.3        ROLE OF END USERS               92

5.9.4        ROLE OF REGULATORY AUTHORITIES      93

5.10         PORTER’S FIVE FORCES ANALYSIS          93

5.10.1      INTENSITY OF COMPETITIVE RIVALRY     94

5.10.2      BARGAINING POWER OF SUPPLIERS      95

5.10.3      BARGAINING POWER OF BUYERS            95

5.10.4      THREAT OF SUBSTITUTES        95

5.10.5      THREAT OF NEW ENTRANTS   96

5.11         KEY STAKEHOLDERS AND BUYING CRITERIA          96

5.11.1      KEY STAKEHOLDERS IN BUYING PROCESS             96

5.11.2      KEY BUYING CRITERIA              97

5.12         REGULATORY LANDSCAPE      98

5.12.1      REGULATORY ANALYSIS          98

5.12.1.1  North America          98

5.12.1.1.1                US             98

5.12.1.1.2                Canada    100

5.12.1.2  Europe     100

5.12.1.3  Asia Pacific               102

5.12.1.3.1                Japan       102

5.12.1.3.2                China       103

5.12.1.3.3                India         103

5.12.1.4  Latin America           104

5.12.1.4.1                Brazil        104

5.13         KEY CONFERENCES AND EVENTS, 2024–2025    105

5.14         INVESTMENT AND FUNDING SCENARIO 107

5.15         IMPACT OF AI/GEN AI ON IMMUNOHISTOCHEMISTRY MARKET              107

6               IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING               110

6.1            INTRODUCTION        111

6.2            ANTIBODIES             111

6.2.1        IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE  114

6.2.2        PRIMARY ANTIBODIES              114

6.2.2.1     Increasing adoption of targeted immunotherapy to drive segment        114

6.2.3        SECONDARY ANTIBODIES        117

6.2.3.1     Better signal amplification and easier manufacturing process to fuel segment growth                  117

6.2.4        IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY         120

6.2.5        MONOCLONAL ANTIBODIES    121

6.2.5.1     Increased applications in cancer diagnostics to support market growth                121

6.2.6        POLYCLONAL ANTIBODIES      124

6.2.6.1     Better sensitivity and higher resistant to changes in antigen conformation to augment segment growth       124

6.3            REAGENTS                126

6.3.1        HISTOLOGICAL STAINS             129

6.3.1.1     Growing focus on cancer diagnostics and developmental research to drive segment                  129

6.3.2        BLOCKING SERA AND REAGENTS            132

6.3.2.1     Need to prevent non-specific binding and provide accurate outcomes to drive adoption                  132

6.3.3        CHROMOGENIC SUBSTRATES 135

6.3.3.1     Rapid detection and faster diagnosis to propel segment growth            135

6.3.4        FIXATION REAGENTS                138

6.3.4.1     Increased focus on retaining tissue morphology and antigenicity of target molecules to support adoption     138

6.3.5        DILUENTS                 141

6.3.5.1     Focus on reducing non-specific background staining during immunostaining to aid segment growth       141

6.3.6        ORGANIC SOLVENTS                144

6.3.6.1     Need to prevent physical damage in specimens and improve clarity in tissue sample visualization to drive market   144

6.3.7        PROTEOLYTIC ENZYMES          146

6.3.7.1     Proteolytic enzymes to improve accessibility of target antibodies          146

6.3.8        OTHER REAGENTS   149

6.4            EQUIPMENT              152

6.4.1        SLIDE-STAINING SYSTEMS      155

6.4.1.1     Availability of technologically advanced slide-staining systems to fuel segment growth                  155

6.4.2        TISSUE PROCESSING SYSTEMS              158

6.4.2.1     High equipment cost and need for extensive regulatory compliance to limit market                  158

6.4.3        SLIDE SCANNERS    161

6.4.3.1     Accurate insights into complexity of tissue interactions and multi-parameter cellular expressions to aid adoption    161

6.4.4        OTHER EQUIPMENT 164

6.5            KITS         166

6.5.1        HUMAN IMMUNOHISTOCHEMISTRY KITS                170

6.5.1.1     Increasing focus on cancer research to fuel segment growth 170

6.5.2        ANIMAL IMMUNOHISTOCHEMISTRY KITS                173

6.5.2.1     Rising focus on drug safety and efficacy in preclinical drug testing to boost segment growth                  173

6.6            SOFTWARE               175

6.6.1        GROWING FOCUS ON DIGITAL PATHOLOGY FOR MORE ACCURATE DIAGNOSIS TO DRIVE MARKET  175

7               IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION          179

7.1            INTRODUCTION        180

7.2            DIAGNOSTIC APPLICATIONS    180

7.2.1        CANCER   184

7.2.1.1     Increasing target population and rising adoption of targeted therapies to propel market growth      184

7.2.2        INFECTIOUS DISEASES            188

7.2.2.1     High prevalence of infectious diseases and need for early diagnosis to aid market growth                  188

7.2.3        NEPHROLOGICAL DISEASES   192

7.2.3.1     Rising prevalence of renal transplant-associated conditions to drive market        192

7.2.4        AUTOIMMUNE DISEASES         195

7.2.4.1     Focus on differentiating autoimmune diseases from similar clinical presentations to augment market growth          195

7.2.5        NEUROLOGICAL DISEASES      198

7.2.5.1     Increasing global burden of neurological disorders to spur market growth            198

7.2.6        OTHER DISEASES    201

7.3            RESEARCH APPLICATIONS      204

7.3.1        DRUG DEVELOPMENT AND TESTING       207

7.3.1.1     Need for accurate and objective outcomes in drug testing to augment segment growth                  207

7.3.2        OTHER RESEARCH APPLICATIONS          210

7.4            FORENSIC APPLICATIONS       213

7.4.1        INCREASED DEMAND FOR EFFECTIVE DETERMINATION OF PATHOLOGICAL CHANGES TO SUPPORT MARKET GROWTH  213

8               IMMUNOHISTOCHEMISTRY MARKET, BY END USER               216

8.1            INTRODUCTION        217

8.2            HOSPITALS AND DIAGNOSTIC LABORATORIES        217

8.2.1        LOW COST OF SPECIALTY DIAGNOSTIC TESTS AND HIGH DEMAND FOR PERSONALIZED MEDICINES TO AID MARKET GROWTH    217

8.3            ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS                  221

8.3.1        GROWING APPLICATION OF IMMUNOHISTOCHEMISTRY TESTS FOR DRUG DEVELOPMENT TO POSITIVELY IMPACT MARKET GROWTH              221

8.4            OTHER END USERS 224

9               IMMUNOHISTOCHEMISTRY MARKET, BY REGION  228

9.1            INTRODUCTION        229

9.2            NORTH AMERICA     229

9.2.1        MACROECONOMIC OUTLOOK FOR NORTH AMERICA               235

9.2.2        US             236

9.2.2.1     US to dominate North American immunohistochemistry market during forecast period                  236

9.2.3        CANADA   240

9.2.3.1     High incidence of cancer and increased demand for advanced diagnostics to propel market growth         240

9.3            EUROPE   244

9.3.1        MACROECONOMIC OUTLOOK FOR EUROPE            249

9.3.2        GERMANY                 250

9.3.2.1     High investments in life science R&D and favorable reimbursement policies to drive market     250

9.3.3        UK            254

9.3.3.1     Rising prevalence of cancer and increasing government funding in health research to augment market growth          254

9.3.4        FRANCE   258

9.3.4.1     Increased research in cancer diagnosis and treatment to support market growth                  258

9.3.5        ITALY        263

9.3.5.1     Advanced health infrastructure and high geriatric population to

fuel market growth  263

9.3.6        SPAIN       267

9.3.6.1     Increased demand for personalized medicines to boost adoption

of immunohistochemistry products        267

9.3.7        REST OF EUROPE    270

9.4            ASIA PACIFIC            274

9.4.1        MACROECONOMIC OUTLOOK FOR ASIA PACIFIC    280

9.4.2        CHINA      281

9.4.2.1     Increasing focus on advanced cancer diagnostics to spur market growth              281

9.4.3        JAPAN      285

9.4.3.1     High geriatric population and increased government healthcare expenditure to support market growth         285

9.4.4        INDIA        289

9.4.4.1     Need for high-end pathology and diagnostic services to propel market growth     289

9.4.5        AUSTRALIA                293

9.4.5.1     Increased patient population and high demand for quality healthcare to aid market growth                  293

9.4.6        SOUTH KOREA         297

9.4.6.1     Focus on precision healthcare and personalized medicines to

drive market            297

9.4.7        REST OF ASIA PACIFIC              301

9.5            LATIN AMERICA        305

9.5.1        MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 309

9.5.2        BRAZIL     310

9.5.2.1     Increasing incidence of chronic lifestyle diseases and rising investments by private companies to fuel market growth            310

9.5.3        MEXICO   314

9.5.3.1     Increasing research initiatives and rising cancer cases to drive market                 314

9.5.4        REST OF LATIN AMERICA         318

9.6            MIDDLE EAST           322

9.6.1        MACROECONOMIC OUTLOOK FOR MIDDLE EAST   326

9.6.2        GCC COUNTRIES      327

9.6.2.1     Saudi Arabia             331

9.6.2.1.1 Growing cancer burden and increasing focus on research to augment market growth                  331

9.6.2.2     UAE           334

9.6.2.2.1 Favorable government initiatives and high investments in healthcare infrastructure to fuel market growth         334

9.6.2.3     Rest of GCC Countries             338

9.6.3        REST OF MIDDLE EAST            342

9.7            AFRICA     345

9.7.1        RAPID RISE IN CANCER CASES AND HIGH HEALTHCARE INVESTMENTS TO DRIVE MARKET                  345

9.7.2        MACROECONOMIC OUTLOOK FOR AFRICA              349

10             COMPETITIVE LANDSCAPE      351

10.1         INTRODUCTION        351

10.2         KEY PLAYER STRATEGY/RIGHT TO WIN  351

10.2.1      OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET                  351

10.3         REVENUE ANALYSIS, 2021–2023          353

10.4         MARKET SHARE ANALYSIS, 2023            354

10.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023            356

10.5.1      STARS      356

10.5.2      EMERGING LEADERS               356

10.5.3      PERVASIVE PLAYERS                356

10.5.4      PARTICIPANTS         356

10.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2023          358

10.5.5.1  Company footprint  358

10.5.5.2  Offering footprint     359

10.5.5.3  Application footprint                 360

10.5.5.4  Region footprint       361

10.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023     362

10.6.1      PROGRESSIVE COMPANIES    362

10.6.2      RESPONSIVE COMPANIES       362

10.6.3      DYNAMIC COMPANIES             362

10.6.4      STARTING BLOCKS 362

10.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023     364

10.7         COMPANY VALUATION AND FINANCIAL METRICS   366

10.7.1      FINANCIAL METRICS                 366

10.7.2      COMPANY VALUATION              366

10.8         BRAND/PRODUCT COMPARISON            367

10.9         COMPETITIVE SCENARIO         368

10.9.1      PRODUCT LAUNCHES AND APPROVALS 368

10.9.2      DEALS      369

10.9.3      EXPANSIONS            370

10.9.4      OTHER DEVELOPMENTS          371

11             COMPANY PROFILES                372

11.1         KEY PLAYERS           372

11.1.1      F. HOFFMANN-LA ROCHE LTD.                 372

11.1.1.1  Business overview  372

11.1.1.2  Products/Solutions offered    373

11.1.1.3  Recent developments              377

11.1.1.3.1                Product launches and approvals             377

11.1.1.3.2                Deals       379

11.1.1.4  MnM view                 380

11.1.1.4.1                Key strengths           380

11.1.1.4.2                Strategic choices     380

11.1.1.4.3                Weaknesses and competitive threats    380

11.1.2      DANAHER CORPORATION        381

11.1.2.1  Business overview  381

11.1.2.2  Products/Solutions offered    382

11.1.2.3  Recent developments              386

11.1.2.3.1                Product launches and approvals             386

11.1.2.3.2                Deals       386

11.1.2.4  MnM view                 387

11.1.2.4.1                Key strengths           387

11.1.2.4.2                Strategic choices     387

11.1.2.4.3                Weaknesses and competitive threats    387

11.1.3      AGILENT TECHNOLOGIES, INC.                 388

11.1.3.1  Business overview  388

11.1.3.2  Products/Solutions offered    389

11.1.3.3  Recent developments              393

11.1.3.3.1                Product launches and approvals             393

11.1.3.3.2                Deals       394

11.1.3.3.3                Expansions               394

11.1.3.4  MnM view                 395

11.1.3.4.1                Key strengths           395

11.1.3.4.2                Strategic choices     395

11.1.3.4.3                Weaknesses and competitive threats    395

11.1.4      PHC HOLDINGS CORPORATION               396

11.1.4.1  Business overview  396

11.1.4.2  Products/Solutions offered    397

11.1.4.3  Recent developments              402

11.1.4.3.1                Deals       402

11.1.4.3.2                Other developments                403

11.1.4.4  MnM view                 403

11.1.4.4.1                Key strengths           403

11.1.4.4.2                Strategic choices     403

11.1.4.4.3                Weaknesses and competitive threats    403

11.1.5      THERMO FISHER SCIENTIFIC INC.            404

11.1.5.1  Business overview  404

11.1.5.2  Products/Solutions offered    405

11.1.6      MERCK KGAA           409

11.1.6.1  Business overview  409

11.1.6.2  Products/Solutions offered    410

11.1.7      BIO-RAD LABORATORIES, INC. 417

11.1.7.1  Business overview  417

11.1.7.2  Products/Solutions offered    418

11.1.8      BIO-TECHNE             422

11.1.8.1  Business overview  422

11.1.8.2  Products/Solutions offered    423

11.1.8.3  Recent developments              426

11.1.8.3.1                Deals       426

11.1.8.3.2                Expansions               426

11.1.8.3.3                Other developments                426

11.1.9      BECTON, DICKINSON AND COMPANY     427

11.1.9.1  Business overview  427

11.1.9.2  Products/Solutions offered    428

11.1.9.3  Recent developments              432

11.1.9.3.1                Expansions               432

11.1.10   TAKARA BIO INC.      433

11.1.10.1                 Business overview  433

11.1.10.2                 Products/Solutions offered    434

11.1.11   ENZO BIOCHEM INC.                 438

11.1.11.1                 Business overview  438

11.1.11.2                 Products/Solutions offered    439

11.1.11.3                 Recent developments              441

11.1.11.3.1              Expansions               441

11.1.12   SINO BIOLOGICAL, INC.            442

11.1.12.1                 Business overview  442

11.1.12.2                 Products/Solutions offered    442

11.1.12.3                 Recent developments              443

11.1.12.3.1              Expansions               443

11.1.13   SAKURA FINETEK JAPAN CO., LTD.          444

11.1.13.1                 Business overview  444

11.1.13.2                 Products/Solutions offered    444

11.1.13.3                 Recent developments              447

11.1.13.3.1              Product launches    447

11.1.13.3.2              Deals       449

11.1.14   CELL SIGNALING TECHNOLOGY, INC.      450

11.1.14.1                 Business overview  450

11.1.14.2                 Products/Solutions offered    450

11.1.14.3                 Recent developments              453

11.1.14.3.1              Deals       453

11.1.15   BIO SB     454

11.1.15.1                 Business overview  454

11.1.15.2                 Products/Solutions offered    454

11.1.15.3                 Recent developments              459

11.1.15.3.1              Product launches    459

11.1.16   MILTENYI BIOTEC    460

11.1.16.1                 Business overview  460

11.1.16.2                 Products/Solutions offered    460

11.1.17   ORIGENE TECHNOLOGIES, INC.                463

11.1.17.1                 Business overview  463

11.1.17.2                 Products/Solutions offered    463

11.2         OTHER PLAYERS      468

11.2.1      EAGLEBIO                 468

11.2.2      BIOCARE MEDICAL, LLC           469

11.2.3      ELABSCIENCE BIONOVATION INC.            471

11.2.4      BIOGENEX                 473

11.2.5      DIAGNOSTIC BIOSYSTEMS INC.               475

11.2.6      HISTO-LINE LABORATORIES    477

11.2.7      ROCKLAND IMMUNOCHEMICALS, INC.   479

11.2.8      CANDOR BIOSCIENCE GMBH  480

11.2.9      GENEMED BIOTECHNOLOGIES, INC.       481

12             APPENDIX                 482

12.1         DISCUSSION GUIDE 482

12.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                486

12.3         CUSTOMIZATION OPTIONS      488

12.4         RELATED REPORTS 488

12.5         AUTHOR DETAILS     489

LIST OF TABLES

TABLE 1   IMMUNOHISTOCHEMISTRY MARKET: INCLUSIONS AND EXCLUSIONS  46

TABLE 2   IMMUNOHISTOCHEMISTRY MARKET: IMPACT ANALYSIS       67

TABLE 3   ESTIMATED NUMBER OF NEW CASES, BY REGION, 2022–2045 (THOUSAND)     68

TABLE 4   ESTIMATED PERCENTAGE INCREASE IN GERIATRIC POPULATION,

BY REGION, 2022–2050        69

TABLE 5   CPT CODES FOR IMMUNOHISTOCHEMISTRY PROCEDURES  71

TABLE 6   MAJOR ACQUISITIONS IN IMMUNOHISTOCHEMISTRY MARKET, 2020–2023        74

TABLE 7   AVERAGE SELLING PRICE FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2023      79

TABLE 8   INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2021–2023 (USD)              80

TABLE 9   INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS,

BY REGION, 2021–2023 (USD)               80

TABLE 10 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014–2024          85

TABLE 11 TOP 20 PATENT OWNERS IN IMMUNOHISTOCHEMISTRY MARKET, 2014–2024 86

TABLE 12 INDICATIVE LIST OF PATENTS IN IMMUNOHISTOCHEMISTRY MARKET, 2022–2024                  87

TABLE 13 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF RAW MATERIAL SUPPLIERS          91

TABLE 14 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF PRODUCT PROVIDERS 92

TABLE 15 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF END USERS  92

TABLE 16 IMMUNOHISTOCHEMISTRY MARKET: ROLE OF REGULATORY AUTHORITIES          93

TABLE 17 IMMUNOHISTOCHEMISTRY MARKET: PORTER’S FIVE FORCES ANALYSIS              93

TABLE 18 BUYING CRITERIA FOR IMMUNOHISTOCHEMISTRY PRODUCTS, BY END USER      97

TABLE 19 US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES        98

TABLE 20 EUROPE: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES                100

TABLE 21 JAPAN: CLASSIFICATION OF IN VITRO DIAGNOSTIC REAGENTS               102

TABLE 22 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS    103

TABLE 23 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS    103

TABLE 24 IMMUNOHISTOCHEMISTRY MARKET: DETAILED LIST OF KEY CONFERENCES

AND EVENTS, JANUARY 2024–DECEMBER 2025  105

TABLE 25 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)                  111

TABLE 26 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGION,

2022–2029 (USD MILLION)   112

TABLE 27 NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                112

TABLE 28 EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   112

TABLE 29 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                113

TABLE 30 LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                113

TABLE 31 MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                113

TABLE 32 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                114

TABLE 33 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   114

TABLE 34 PRIMARY ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)            115

TABLE 35 NORTH AMERICA: PRIMARY ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   115

TABLE 36 EUROPE: PRIMARY ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   116

TABLE 37 ASIA PACIFIC: PRIMARY ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   116

TABLE 38 LATIN AMERICA: PRIMARY ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   116

TABLE 39 MIDDLE EAST: PRIMARY ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   117

TABLE 40 GCC COUNTRIES: PRIMARY ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   117

TABLE 41 SECONDARY ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)      118

TABLE 42 NORTH AMERICA: SECONDARY ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   118

TABLE 43 EUROPE: SECONDARY ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   119

TABLE 44 ASIA PACIFIC: SECONDARY ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   119

TABLE 45 LATIN AMERICA: SECONDARY ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   119

TABLE 46 MIDDLE EAST: SECONDARY ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   120

TABLE 47 GCC COUNTRIES: SECONDARY ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   120

TABLE 48 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2022–2029 (USD MILLION)   120

TABLE 49 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)   121

TABLE 50 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   122

TABLE 51 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   122

TABLE 52 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   122

TABLE 53 LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   123

TABLE 54 MIDDLE EAST: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   123

TABLE 55 GCC COUNTRIES: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   123

TABLE 56 POLYCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)     124

TABLE 57 NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   124

TABLE 58 EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   125

TABLE 59 ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   125

TABLE 60 LATIN AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   125

TABLE 61 MIDDLE EAST: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   126

TABLE 62 GCC COUNTRIES: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   126

TABLE 63 IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   127

TABLE 64 IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY REGION,

2022–2029 (USD MILLION)   127

TABLE 65 NORTH AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   127

TABLE 66 EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   128

TABLE 67 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   128

TABLE 68 LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                128

TABLE 69 MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                129

TABLE 70 GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                129

TABLE 71 HISTOLOGICAL STAINS MARKET, BY REGION, 2022–2029 (USD MILLION)           130

TABLE 72 NORTH AMERICA: HISTOLOGICAL STAINS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   130

TABLE 73 EUROPE: HISTOLOGICAL STAINS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   131

TABLE 74 ASIA PACIFIC: HISTOLOGICAL STAINS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   131

TABLE 75 LATIN AMERICA: HISTOLOGICAL STAINS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   131

TABLE 76 MIDDLE EAST: HISTOLOGICAL STAINS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   132

TABLE 77 GCC COUNTRIES: HISTOLOGICAL STAINS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   132

TABLE 78 BLOCKING SERA AND REAGENTS MARKET, BY REGION,

2022–2029 (USD MILLION)   133

TABLE 79 NORTH AMERICA: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   133

TABLE 80 EUROPE: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   133

TABLE 81 ASIA PACIFIC: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   134

TABLE 82 LATIN AMERICA: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   134

TABLE 83 MIDDLE EAST: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   134

TABLE 84 GCC COUNTRIES: BLOCKING SERA AND REAGENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   135

TABLE 85 CHROMOGENIC SUBSTRATES MARKET, BY REGION, 2022–2029 (USD MILLION)                  136

TABLE 86 NORTH AMERICA: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   136

TABLE 87 EUROPE: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   136

TABLE 88 ASIA PACIFIC: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   137

TABLE 89 LATIN AMERICA: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   137

TABLE 90 MIDDLE EAST: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   137

TABLE 91 GCC COUNTRIES: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   138

TABLE 92 FIXATION REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)               139

TABLE 93 NORTH AMERICA: FIXATION REAGENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   139

TABLE 94 EUROPE: FIXATION REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                  139

TABLE 95 ASIA PACIFIC: FIXATION REAGENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   140

TABLE 96 LATIN AMERICA: FIXATION REAGENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   140

TABLE 97 MIDDLE EAST: FIXATION REAGENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   140

TABLE 98 GCC COUNTRIES: FIXATION REAGENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   141

TABLE 99 DILUENTS MARKET, BY REGION, 2022–2029 (USD MILLION)                141

TABLE 100               NORTH AMERICA: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 142

TABLE 101               EUROPE: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                  142

TABLE 102               ASIA PACIFIC: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                  142

TABLE 103               LATIN AMERICA: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                  143

TABLE 104               MIDDLE EAST: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                  143

TABLE 105               GCC COUNTRIES: DILUENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 143

TABLE 106               ORGANIC SOLVENTS MARKET, BY REGION, 2022–2029 (USD MILLION)                  144

TABLE 107               NORTH AMERICA: ORGANIC SOLVENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   144

TABLE 108               EUROPE: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 145

TABLE 109               ASIA PACIFIC: ORGANIC SOLVENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   145

TABLE 110               LATIN AMERICA: ORGANIC SOLVENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   145

TABLE 111               MIDDLE EAST: ORGANIC SOLVENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   146

TABLE 112               GCC COUNTRIES: ORGANIC SOLVENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   146

TABLE 113               PROTEOLYTIC ENZYMES MARKET, BY REGION, 2022–2029 (USD MILLION)                  147

TABLE 114               NORTH AMERICA: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   147

TABLE 115               EUROPE: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   147

TABLE 116               ASIA PACIFIC: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   148

TABLE 117               LATIN AMERICA: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   148

TABLE 118               MIDDLE EAST: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   148

TABLE 119               GCC COUNTRIES: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   149

TABLE 120               OTHER REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION) 150

TABLE 121               NORTH AMERICA: OTHER REAGENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   150

TABLE 122               EUROPE: OTHER REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 150

TABLE 123               ASIA PACIFIC: OTHER REAGENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   151

TABLE 124               LATIN AMERICA: OTHER REAGENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   151

TABLE 125               MIDDLE EAST: OTHER REAGENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   151

TABLE 126               GCC COUNTRIES: OTHER REAGENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   152

TABLE 127               IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   152

TABLE 128               IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY REGION,

2022–2029 (USD MILLION)   153

TABLE 129               NORTH AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)  153

TABLE 130               EUROPE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   153

TABLE 131               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)   154

TABLE 132              LATIN AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)   154

TABLE 133               MIDDLE EAST: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)   154

TABLE 134               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)  155

TABLE 135               IMMUNOHISTOCHEMISTRY SLIDE-STAINING SYSTEMS MARKET, BY VOLUME, 2022–2029 (UNITS)                155

TABLE 136               SLIDE-STAINING SYSTEMS MARKET, BY REGION, 2022–2029 (USD MILLION)                  156

TABLE 137               NORTH AMERICA: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   156

TABLE 138               EUROPE: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   156

TABLE 139               ASIA PACIFIC: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   157

TABLE 140               LATIN AMERICA: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   157

TABLE 141               MIDDLE EAST: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   157

TABLE 142               GCC COUNTRIES: SLIDE-STAINING SYSTEMS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   158

TABLE 143               TISSUE PROCESSING SYSTEMS MARKET, BY REGION, 2022–2029 (USD MILLION) 158

TABLE 144               NORTH AMERICA: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   159

TABLE 145               EUROPE: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   159

TABLE 146               ASIA PACIFIC: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   159

TABLE 147               LATIN AMERICA: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   160

TABLE 148               MIDDLE EAST: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   160

TABLE 149               GCC COUNTRIES: TISSUE PROCESSING SYSTEMS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   160

TABLE 150               SLIDE SCANNERS MARKET, BY REGION, 2022–2029 (USD MILLION)  161

TABLE 151               NORTH AMERICA: SLIDE SCANNERS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   162

TABLE 152               EUROPE: SLIDE SCANNERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)                  162

TABLE 153               ASIA PACIFIC: SLIDE SCANNERS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   162

TABLE 154               LATIN AMERICA: SLIDE SCANNERS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   163

TABLE 155               MIDDLE EAST: SLIDE SCANNERS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   163

TABLE 156               GCC COUNTRIES: SLIDE SCANNERS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   163

TABLE 157               OTHER EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION)                  164

TABLE 158               NORTH AMERICA: OTHER EQUIPMENT MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   164

TABLE 159               EUROPE: OTHER EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 165

TABLE 160               ASIA PACIFIC: OTHER EQUIPMENT MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   165

TABLE 161               LATIN AMERICA: OTHER EQUIPMENT MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   165

TABLE 162               MIDDLE EAST: OTHER EQUIPMENT MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   166

TABLE 163               GCC COUNTRIES: OTHER EQUIPMENT MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   166

TABLE 164               IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)                  167

TABLE 165               IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION, 2022–2029 (USD MILLION) 167

TABLE 166               NORTH AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   167

TABLE 167               EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   168

TABLE 168               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   168

TABLE 169               LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   169

TABLE 170               MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   169

TABLE 171               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   169

TABLE 172               HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION,

2022–2029 (USD MILLION)   170

TABLE 173               NORTH AMERICA: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)  170

TABLE 174               EUROPE: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   171

TABLE 175               ASIA PACIFIC: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)   171

TABLE 176               LATIN AMERICA: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)  172

TABLE 177               MIDDLE EAST: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)   172

TABLE 178               GCC COUNTRIES: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)  172

TABLE 179               ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION,

2022–2029 (USD MILLION)   173

TABLE 180               NORTH AMERICA: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)  173

TABLE 181               EUROPE: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   174

TABLE 182               ASIA PACIFIC: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)   174

TABLE 183               LATIN AMERICA: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)  174

TABLE 184               MIDDLE EAST: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)   175

TABLE 185               GCC COUNTRIES: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)  175

TABLE 186               IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY REGION,

2022–2029 (USD MILLION)   176

TABLE 187               NORTH AMERICA: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)  176

TABLE 188               EUROPE: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   176

TABLE 189               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)   177

TABLE 190               LATIN AMERICA: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)   177

TABLE 191               MIDDLE EAST: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)   177

TABLE 192               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)  178

TABLE 193               IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 180

TABLE 194               IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE,

2022–2029 (USD MILLION)   181

TABLE 195               IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2022–2029 (USD MILLION)   181

TABLE 196               NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)              181

TABLE 197               EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)              182

TABLE 198               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)              182

TABLE 199               LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)              183

TABLE 200              MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)              183

TABLE 201               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)              183

TABLE 202               COMMON CANCER MARKERS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS                  184

TABLE 203               IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER,

BY REGION, 2022–2029 (USD MILLION)                 186

TABLE 204               NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)       186

TABLE 205               EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)              186

TABLE 206               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)      187

TABLE 207               LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)       187

TABLE 208               MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)      187

TABLE 209               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)       188

TABLE 210               COMMON INFECTIOUS DISEASE MARKERS/ANTIGENS FOR IMMUNOHISTOCHEMICAL DIAGNOSIS    189

TABLE 211               IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR

INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)          189

TABLE 212               NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)                 190

TABLE 213               EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)       190

TABLE 214               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)                190

TABLE 215               LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)                 191

TABLE 216               MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)                191

TABLE 217               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)                 191

TABLE 218               IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION) 192

TABLE 219               NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)        193

TABLE 220               EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)               193

TABLE 221               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)       193

TABLE 222               LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)        194

TABLE 223               MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)       194

TABLE 224               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)        194

TABLE 225               IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022–2029 (USD MILLION)      195

TABLE 226               NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)              196

TABLE 227               EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)   196

TABLE 228               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)            196

TABLE 229               LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)              197

TABLE 230               MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)            197

TABLE 231               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)              197

TABLE 232               COMMON IMMUNOHISTOCHEMISTRY MARKERS FOR NEUROLOGICAL DISEASES                 198

TABLE 233               IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION)   199

TABLE 234               NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)          199

TABLE 235               EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 199

TABLE 236               ASIA PACIFIC: I IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)         200

TABLE 237               LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)          200

TABLE 238               MIDDLE EAST IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)         200

TABLE 239               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)          201

TABLE 240               IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR

OTHER DISEASES, BY REGION, 2022–2029 (USD MILLION) 201

TABLE 241               NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)         202

TABLE 242               EUROPE IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)                202

TABLE 243               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)       202

TABLE 244               LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)         203

TABLE 245               MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)       203

TABLE 246               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)         203

TABLE 247               IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE,

2022–2029 (USD MILLION)   204

TABLE 248               IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY REGION, 2022–2029 (USD MILLION)   204

TABLE 249               NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)              205

TABLE 250               EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)              205

TABLE 251               ASIA PACIFIC IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)              205

TABLE 252               LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)              206

TABLE 253               MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)              206

TABLE 254               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)              206

TABLE 255               IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY REGION, 2022–2029 (USD MILLION)               208

TABLE 256               NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY,

2022–2029 (USD MILLION)   208

TABLE 257               EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022–2029 (USD MILLION) 208

TABLE 258               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022–2029 (USD MILLION)          209

TABLE 259               LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY,

2022–2029 (USD MILLION)   209

TABLE 260               MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY, 2022–2029 (USD MILLION)          209

TABLE 261               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT AND TESTING, BY COUNTRY,

2022–2029 (USD MILLION)   210

TABLE 262               IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR

OTHER RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)        210

TABLE 263               NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)                  211

TABLE 264               EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)     211

TABLE 265               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)              211

TABLE 266               LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)                  212

TABLE 267               MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)              212

TABLE 268               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)                  212

TABLE 269               IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY REGION,

2022–2029 (USD MILLION)   213

TABLE 270               NORTH AMERICA: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)              213

TABLE 271               EUROPE: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)              214

TABLE 272               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)              214

TABLE 273               LATIN AMERICA: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)              215

TABLE 274               MIDDLE EAST: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)              215

TABLE 275               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)              215

TABLE 276               IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION) 217

TABLE 277               IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION)     218

TABLE 278               NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS

AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)     218

TABLE 279               EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND

DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)              219

TABLE 280               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)              219

TABLE 281               LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)              220

TABLE 282               MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)              220

TABLE 283               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)              220

TABLE 284               IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD MILLION)      221

TABLE 285               NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)         222

TABLE 286               EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,

2022–2029 (USD MILLION)   222

TABLE 287               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,

2022–2029 (USD MILLION)   223

TABLE 288               LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,

2022–2029 (USD MILLION)   223

TABLE 289               MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,

2022–2029 (USD MILLION)   223

TABLE 290               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)         224

TABLE 291               IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY REGION,

2022–2029 (USD MILLION)   225

TABLE 292               NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2029 (USD MILLION)              225

TABLE 293               EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2029 (USD MILLION)              225

TABLE 294               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2029 (USD MILLION)              226

TABLE 295               LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2029 (USD MILLION)              226

TABLE 296               MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2029 (USD MILLION)              226

TABLE 297               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2029 (USD MILLION)              227

TABLE 298               IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2022–2029 (USD MILLION)                  229

TABLE 299               NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   231

TABLE 300               NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   231

TABLE 301               NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)   231

TABLE 302               NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)                 232

TABLE 303               NORTH AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)   232

TABLE 304               NORTH AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)   233

TABLE 305               NORTH AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   233

TABLE 306               NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   233

TABLE 307               NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)     234

TABLE 308               NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)     234

TABLE 309               NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   234

TABLE 310               NORTH AMERICA: KEY MACROINDICATORS            235

TABLE 311               US: RECENT DEVELOPMENTS IN IMMUNOHISTOCHEMISTRY MARKET 236

TABLE 312               US: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   237

TABLE 313               US: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   237

TABLE 314               US: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2022–2029 (USD MILLION)   238

TABLE 315               US: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   238

TABLE 316               US: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   238

TABLE 317               US: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   239

TABLE 318               US: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   239

TABLE 319               US: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)   239

TABLE 320               US: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)   240

TABLE 321               US: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   240

TABLE 322               CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   241

TABLE 323               CANADA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   241

TABLE 324               CANADA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2022–2029 (USD MILLION)   241

TABLE 325               CANADA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   242

TABLE 326               CANADA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   242

TABLE 327               CANADA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   243

TABLE 328               CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   243

TABLE 329               CANADA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY TYPE, 2022–2029 (USD MILLION)    243

TABLE 330               CANADA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)          244

TABLE 331               CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   244

TABLE 332               EUROPE: RECENT DEVELOPMENTS IN IMMUNOHISTOCHEMISTRY MARKET                  245

TABLE 333               EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   245

TABLE 334               EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   246

TABLE 335               EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   246

TABLE 336               EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2022–2029 (USD MILLION)   246

TABLE 337               EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   247

TABLE 338               EUROPE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   247

TABLE 339               EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   248

TABLE 340               EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   248

TABLE 341               EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY TYPE, 2022–2029 (USD MILLION)    248

TABLE 342               EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)          249

TABLE 343               EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   249

TABLE 344               EUROPE: KEY MACROINDICATORS          250

TABLE 345               GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   251

TABLE 346               GERMANY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   251

TABLE 347               GERMANY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)   252

TABLE 348               GERMANY: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   252

TABLE 349               GERMANY: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   252

TABLE 350               GERMANY: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   253

TABLE 351               GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   253

TABLE 352               GERMANY: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY TYPE, 2022–2029 (USD MILLION)    253

TABLE 353               GERMANY: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY TYPE, 2022–2029 (USD MILLION)    254

TABLE 354               GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   254

TABLE 355               UK: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   255

TABLE 356               UK: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   255

TABLE 357               UK: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2022–2029 (USD MILLION)   256

TABLE 358               UK: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   256

TABLE 359               UK: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   256

TABLE 360               UK: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   257

TABLE 361               UK: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   257

TABLE 362               UK: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)   257

TABLE 363               UK: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)   258

TABLE 364               UK: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   258

TABLE 365               FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   259

TABLE 366               FRANCE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   259

TABLE 367               FRANCE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2022–2029 (USD MILLION)   260

TABLE 368               FRANCE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   260

TABLE 369               FRANCE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   261

TABLE 370               FRANCE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   261

TABLE 371               FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   261

TABLE 372               FRANCE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY TYPE, 2022–2029 (USD MILLION)    262

TABLE 373               FRANCE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)          262

TABLE 374               FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   262

TABLE 375               ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   263

TABLE 376               ITALY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   263

TABLE 377               ITALY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2022–2029 (USD MILLION)   264

TABLE 378               ITALY: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   264

TABLE 379               ITALY: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   265

TABLE 380               ITALY: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   265

TABLE 381               ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   265

TABLE 382               ITALY: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)          266

TABLE 383               ITALY: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)   266

TABLE 384               ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   266

TABLE 385               SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   267

TABLE 386               SPAIN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   267

TABLE 387               SPAIN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2022–2029 (USD MILLION)   268

TABLE 388               SPAIN: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   268

TABLE 389               SPAIN: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   268

TABLE 390               SPAIN: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   269

TABLE 391               SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   269

TABLE 392               SPAIN: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)          269

TABLE 393              SPAIN: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)   270

TABLE 394               SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   270

TABLE 395               REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   271

TABLE 396               REST OF EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)   271

TABLE 397               REST OF EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)                 271

TABLE 398               REST OF EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)   272

TABLE 399               REST OF EUROPE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)   272

TABLE 400               REST OF EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   273

TABLE 401               REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   273

TABLE 402               REST OF EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)     273

TABLE 403               REST OF EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)     274

TABLE 404               REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   274

TABLE 405               ASIA PACIFIC: RECENT DEVELOPMENTS IN IMMUNOHISTOCHEMISTRY MARKET                  275

TABLE 406               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   276

TABLE 407               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   276

TABLE 408               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   277

TABLE 409               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)   277

TABLE 410               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   277

TABLE 411               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   278

TABLE 412               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   278

TABLE 413               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   278

TABLE 414               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY TYPE, 2022–2029 (USD MILLION)    279

TABLE 415               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY TYPE, 2022–2029 (USD MILLION)    279

TABLE 416               ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   279

TABLE 417               ASIA PACIFIC: KEY MACROINDICATORS  281

TABLE 418               CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   282

TABLE 419               CHINA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   282

TABLE 420               CHINA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2022–2029 (USD MILLION)   283

TABLE 421               CHINA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   283

TABLE 422               CHINA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   283

TABLE 423               CHINA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   284

TABLE 424               CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   284

TABLE 425               CHINA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)          284

TABLE 426               CHINA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)          285

TABLE 427               CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   285

TABLE 428               JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   286

TABLE 429               JAPAN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   286

TABLE 430               JAPAN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2022–2029 (USD MILLION)   286

TABLE 431               JAPAN: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   287

TABLE 432               JAPAN: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   287

TABLE 433               JAPAN: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   287

TABLE 434               JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   288

TABLE 435               JAPAN: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)          288

TABLE 436               JAPAN: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)          288

TABLE 437               JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   289

TABLE 438               INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   290

TABLE 439               INDIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   290

TABLE 440               INDIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2022–2029 (USD MILLION)   290

TABLE 441               INDIA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   291

TABLE 442               INDIA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   291

TABLE 443               INDIA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   292

TABLE 444               INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   292

TABLE 445               INDIA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)          292

TABLE 446               INDIA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)   293

TABLE 447               INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   293

TABLE 448               AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   294

TABLE 449               AUSTRALIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   294

TABLE 450               AUSTRALIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)   295

TABLE 451               AUSTRALIA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   295

TABLE 452               AUSTRALIA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   295

TABLE 453               AUSTRALIA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   296

TABLE 454               AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   296

TABLE 455               AUSTRALIA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY TYPE, 2022–2029 (USD MILLION)    296

TABLE 456               AUSTRALIA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY TYPE, 2022–2029 (USD MILLION)    297

TABLE 457               AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   297

TABLE 458               SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   298

TABLE 459               SOUTH KOREA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   298

TABLE 460               SOUTH KOREA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)                 298

TABLE 461               SOUTH KOREA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   299

TABLE 462               SOUTH KOREA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   299

TABLE 463               SOUTH KOREA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   300

TABLE 464               SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   300

TABLE 465               SOUTH KOREA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)     300

TABLE 466               SOUTH KOREA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY TYPE, 2022–2029 (USD MILLION)    301

TABLE 467               SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   301

TABLE 468               REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   302

TABLE 469               REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)          302

TABLE 470               REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY CLONALITY, 2022–2029 (USD MILLION)           303

TABLE 471               REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)          303

TABLE 472               REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)          303

TABLE 473               REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   304

TABLE 474               REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)   304

TABLE 475               REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)     304

TABLE 476               REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)     305

TABLE 477               REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   305

TABLE 478               LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   306

TABLE 479               LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   306

TABLE 480               LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)   306

TABLE 481               LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)                 307

TABLE 482               LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   307

TABLE 483               LATIN AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   307

TABLE 484               LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   308

TABLE 485               LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   308

TABLE 486               LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)     308

TABLE 487               LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)     309

TABLE 488               LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   309

TABLE 489               LATIN AMERICA: KEY MACROINDICATORS               310

TABLE 490               BRAZIL: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   311

TABLE 491               BRAZIL: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   311

TABLE 492               BRAZIL: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2022–2029 (USD MILLION)   311

TABLE 493               BRAZIL: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   312

TABLE 494               BRAZIL: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   312

TABLE 495               BRAZIL: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   313

TABLE 496               BRAZIL: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   313

TABLE 497               BRAZIL: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)          313

TABLE 498               BRAZIL: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)          314

TABLE 499               BRAZIL: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   314

TABLE 500               MEXICO: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   315

TABLE 501               MEXICO: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   315

TABLE 502               MEXICO: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2022–2029 (USD MILLION)   315

TABLE 503               MEXICO: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   316

TABLE 504               MEXICO: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   316

TABLE 505               MEXICO: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   316

TABLE 506               MEXICO: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   317

TABLE 507               MEXICO: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY TYPE, 2022–2029 (USD MILLION)    317

TABLE 508               MEXICO: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)          317

TABLE 509               MEXICO: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   318

TABLE 510               REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)   318

TABLE 511               REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)    319

TABLE 512               REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY CLONALITY, 2022–2029 (USD MILLION)           319

TABLE 513               REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET,

BY TYPE, 2022–2029 (USD MILLION)    319

TABLE 514               REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET,

BY TYPE, 2022–2029 (USD MILLION)    320

TABLE 515               REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)   320

TABLE 516              REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)   320

TABLE 517               REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)             321

TABLE 518               REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)     321

TABLE 519               REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)   321

TABLE 520               MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   322

TABLE 521               MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   322

TABLE 522               MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   323

TABLE 523              MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2022–2029 (USD MILLION)   323

TABLE 524               MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   323

TABLE 525               MIDDLE EAST: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   324

TABLE 526               MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   324

TABLE 527               MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   324

TABLE 528              MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY TYPE, 2022–2029 (USD MILLION)    325

TABLE 529               MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY TYPE, 2022–2029 (USD MILLION)    325

TABLE 530               MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   325

TABLE 531               MIDDLE EAST: KEY MACROINDICATORS 326

TABLE 532               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,

2022–2029 (USD MILLION)   327

TABLE 533               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   327

TABLE 534               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)   328

TABLE 535               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2022–2029 (USD MILLION)                 328

TABLE 536               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   328

TABLE 537               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   329

TABLE 538               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   329

TABLE 539               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   329

TABLE 540               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)     330

TABLE 541               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)     330

TABLE 542               GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   330

TABLE 543               SAUDI ARABIA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   331

TABLE 544               SAUDI ARABIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   331

TABLE 545               SAUDI ARABIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2022–2029 (USD MILLION)   332

TABLE 546               SAUDI ARABIA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   332

TABLE 547               SAUDI ARABIA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   332

TABLE 548               SAUDI ARABIA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   333

TABLE 549               SAUDI ARABIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   333

TABLE 550              SAUDI ARABIA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)    333

TABLE 551               SAUDI ARABIA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY TYPE, 2022–2029 (USD MILLION)    334

TABLE 552               SAUDI ARABIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   334

TABLE 553               UAE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   335

TABLE 554               UAE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   335

TABLE 555               UAE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2022–2029 (USD MILLION)   335

TABLE 556               UAE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   336

TABLE 557               UAE: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   336

TABLE 558               UAE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   336

TABLE 559               UAE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   337

TABLE 560               UAE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE,

2022–2029 (USD MILLION)   337

TABLE 561               UAE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE,

2022–2029 (USD MILLION)   337

TABLE 562               UAE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   338

TABLE 563               REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2022–2029 (USD MILLION)   338

TABLE 564               REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)    339

TABLE 565               REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY CLONALITY, 2022–2029 (USD MILLION)           339

TABLE 566               REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET,

BY TYPE, 2022–2029 (USD MILLION)    339

TABLE 567               REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET,

BY TYPE, 2022–2029 (USD MILLION)    340

TABLE 568               REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2022–2029 (USD MILLION)   340

TABLE 569               REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)             340

TABLE 570               REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)             341

TABLE 571               REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)             341

TABLE 572               REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)   341

TABLE 573               REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   342

TABLE 574               REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)          342

TABLE 575               REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY CLONALITY, 2022–2029 (USD MILLION)           343

TABLE 576               REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)          343

TABLE 577               REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)          343

TABLE 578               REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   344

TABLE 579               REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)   344

TABLE 580               REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)     344

TABLE 581               REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)     345

TABLE 582               REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2022–2029 (USD MILLION)   345

TABLE 583               AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2022–2029 (USD MILLION)   346

TABLE 584               AFRICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2022–2029 (USD MILLION)   346

TABLE 585               AFRICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2022–2029 (USD MILLION)   346

TABLE 586               AFRICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2022–2029 (USD MILLION)   347

TABLE 587               AFRICA: IMMUNOHISTOCHEMISTRY EQUIPMENT MARKET, BY TYPE,

2022–2029 (USD MILLION)   347

TABLE 588               AFRICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2022–2029 (USD MILLION)   348

TABLE 589               AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2022–2029 (USD MILLION)   348

TABLE 590               AFRICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)          348

TABLE 591               AFRICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)          349

TABLE 592               AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2022–2029 (USD MILLION)   349

TABLE 593               AFRICA: KEY MACROINDICATORS            350

TABLE 594               OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET      351

TABLE 595               IMMUNOHISTOCHEMISTRY MARKET: DEGREE OF COMPETITION          354

TABLE 596               IMMUNOHISTOCHEMISTRY MARKET: OFFERING FOOTPRINT 359

TABLE 597               IMMUNOHISTOCHEMISTRY MARKET: APPLICATION FOOTPRINT            360

TABLE 598               IMMUNOHISTOCHEMISTRY MARKET: REGION FOOTPRINT    361

TABLE 599               IMMUNOHISTOCHEMISTRY MARKET: DETAILED LIST OF

KEY STARTUP/SME PLAYERS 364

TABLE 600               IMMUNOHISTOCHEMISTRY MARKET: COMPETITIVE BENCHMARKING OF

KEY EMERGING PLAYERS/STARTUPS    365

TABLE 601               IMMUNOHISTOCHEMISTRY MARKET: PRODUCT LAUNCHES AND

APPROVALS, JANUARY 2021–JULY 2024                368

TABLE 602               IMMUNOHISTOCHEMISTRY MARKET: DEALS, JANUARY 2021–JULY 2024                  369

TABLE 603               IMMUNOHISTOCHEMISTRY MARKET: EXPANSIONS, JANUARY 2021–JULY 2024                  370

TABLE 604               IMMUNOHISTOCHEMISTRY MARKET: OTHER DEVELOPMENTS,

JANUARY 2021–JULY 2024    371

TABLE 605               F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW            372

TABLE 606               F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SOLUTIONS OFFERED        373

TABLE 607               F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2021–JULY 2024    377

TABLE 608               F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–JULY 2024      379

TABLE 609               DANAHER CORPORATION: COMPANY OVERVIEW   381

TABLE 610               DANAHER CORPORATION: PRODUCTS/SOLUTIONS OFFERED                382

TABLE 611               DANAHER CORPORATION: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2021–JULY 2024    386

TABLE 612               DANAHER CORPORATION: DEALS, JANUARY 2021–JULY 2024              386

TABLE 613               AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW            388

TABLE 614               AGILENT TECHNOLOGIES, INC.: PRODUCTS/SOLUTIONS OFFERED       389

TABLE 615               AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2021–JULY 2024    393

TABLE 616               AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021–JULY 2024     394

TABLE 617               AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021–JULY 2024                  394

TABLE 618               PHC HOLDINGS CORPORATION: COMPANY OVERVIEW           396

TABLE 619               PHC HOLDINGS CORPORATION: PRODUCTS/SOLUTIONS OFFERED      397

TABLE 620               PHC HOLDINGS CORPORATION: DEALS, JANUARY 2021– JULY 2024   402

TABLE 621               PHC HOLDINGS CORPORATION: OTHER DEVELOPMENTS,

JANUARY 2021–JULY 2024    403

TABLE 622               THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW       404

TABLE 623               THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SOLUTIONS OFFERED  405

TABLE 624               MERCK KGAA: COMPANY OVERVIEW      409

TABLE 625               MERCK KGAA: PRODUCTS/SOLUTIONS OFFERED 410

TABLE 626               BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW             417

TABLE 627               BIO-RAD LABORATORIES, INC.: PRODUCTS/SOLUTIONS OFFERED        418

TABLE 628               BIO-TECHNE: COMPANY OVERVIEW        422

TABLE 629               BIO-TECHNE: PRODUCTS/SOLUTIONS OFFERED    423

TABLE 630               BIO-TECHNE: DEALS, JANUARY 2021– JULY 2024 426

TABLE 631               BIO-TECHNE: EXPANSIONS, JANUARY 2021– JULY 2024       426

TABLE 632               BIO-TECHNE: OTHER DEVELOPMENTS, JANUARY 2021– JULY 2024     426

TABLE 633               BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 427

TABLE 634               BECTON, DICKINSON AND COMPANY: PRODUCTS/SOLUTIONS OFFERED                  428

TABLE 635               BECTON, DICKINSON AND COMPANY: EXPANSIONS, JANUARY 2021– JULY 2024        432

TABLE 636               TAKARA BIO INC.: COMPANY OVERVIEW 433

TABLE 637               TAKARA BIO INC.: PRODUCTS/SOLUTIONS OFFERED             434

TABLE 638               ENZO BIOCHEM INC.: COMPANY OVERVIEW           438

TABLE 639               ENZO BIOCHEM INC.: PRODUCTS/SOLUTIONS OFFERED       439

TABLE 640               ENZO BIOCHEM INC.: EXPANSIONS, JANUARY 2021–JULY 2024           441

TABLE 641               SINO BIOLOGICAL, INC.: COMPANY OVERVIEW       442

TABLE 642               SINO BIOLOGICAL, INC.: PRODUCTS/SOLUTIONS OFFERED  442

TABLE 643               SINO BIOLOGICAL, INC.: EXPANSIONS, JANUARY 2021–JULY 2024       443

TABLE 644               SAKURA FINETEK JAPAN CO., LTD.: COMPANY OVERVIEW     444

TABLE 645               SAKURA FINETEK JAPAN CO., LTD.: PRODUCTS/SOLUTIONS OFFERED 444

TABLE 646               SAKURA FINETEK JAPAN CO., LTD.: PRODUCT LAUNCHES,

JANUARY 2021–JULY 2024    447

TABLE 647               SAKURA FINETEK JAPAN CO., LTD.: DEALS, JANUARY 2021–JULY 2024                  449

TABLE 648               CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW 450

TABLE 649               CELL SIGNALING TECHNOLOGY, INC.: PRODUCTS/SOLUTIONS OFFERED                  450

TABLE 650               CELL SIGNALING TECHNOLOGY, INC.: DEALS, JANUARY 2021–JULY 2024                  453

TABLE 651               BIO SB: COMPANY OVERVIEW 454

TABLE 652               BIO SB: PRODUCTS/SOLUTIONS OFFERED             454

TABLE 653               BIO SB: PRODUCT LAUNCHES, JANUARY 2021–JULY 2024   459

TABLE 654               MILTENYI BIOTEC: COMPANY OVERVIEW                 460

TABLE 655               MILTENYI BIOTEC: PRODUCTS/SOLUTIONS OFFERED            460

TABLE 656               ORIGENE TECHNOLOGIES, INC.: COMPANY OVERVIEW           463

TABLE 657               ORIGENE TECHNOLOGIES, INC.: PRODUCTS/SOLUTIONS OFFERED      463

TABLE 658               EAGLEBIO: COMPANY OVERVIEW            468

TABLE 659               BIOCARE MEDICAL, LLC: COMPANY OVERVIEW      469

TABLE 660               ELABSCIENCE BIONOVATION INC.: COMPANY OVERVIEW       471

TABLE 661               BIOGENEX: COMPANY OVERVIEW            473

TABLE 662               DIAGNOSTIC BIOSYSTEMS INC.: COMPANY OVERVIEW           475

TABLE 663               HISTO-LINE LABORATORIES: COMPANY OVERVIEW                 477

TABLE 664               ROCKLAND IMMUNOCHEMICALS, INC.: COMPANY OVERVIEW                479

TABLE 665               CANDOR BIOSCIENCE GMBH: COMPANY OVERVIEW               480

TABLE 666               GENEMED BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW  481

LIST OF FIGURES

FIGURE 1 IMMUNOHISTOCHEMISTRY MARKET: SEGMENTS & REGIONS COVERED               47

FIGURE 2 IMMUNOHISTOCHEMISTRY MARKET: YEARS CONSIDERED   48

FIGURE 3 IMMUNOHISTOCHEMISTRY MARKET: RESEARCH DESIGN     50

FIGURE 4 IMMUNOHISTOCHEMISTRY MARKET: BREAKDOWN OF PRIMARIES      52

FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2023) 53

FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2023)            53

FIGURE 7 ILLUSTRATIVE EXAMPLE OF F. HOFFMAN-LA ROCHE LTD.:

REVENUE SHARE ANALYSIS (2023)        54

FIGURE 8 MARKET VALIDATION FROM PRIMARY EXPERTS    55

FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH    55

FIGURE 10                IMMUNOHISTOCHEMISTRY MARKET: CAGR PROJECTION, 2024–2029                  57

FIGURE 11                IMMUNOHISTOCHEMISTRY MARKET: GROWTH ANALYSIS OF

DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES                 57

FIGURE 12                DATA TRIANGULATION METHODOLOGY  58

FIGURE 13                IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION) 60

FIGURE 14                IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2024 VS. 2029 (USD MILLION)                61

FIGURE 15                IMMUNOHISTOCHEMISTRY MARKET, BY END USER,

2024 VS. 2029 (USD MILLION)                61

FIGURE 16                IMMUNOHISTOCHEMISTRY MARKET: REGIONAL SNAPSHOT 62

FIGURE 17                GROWING PREVALENCE OF CANCER AND INCREASING

HEALTHCARE EXPENDITURE TO DRIVE MARKET    63

FIGURE 18                US AND DIAGNOSTIC APPLICATIONS DOMINATED NORTH AMERICAN MARKET

IN 2023   64

FIGURE 19                ANTIBODIES TO DOMINATE IMMUNOHISTOCHEMISTRY MARKET IN 2029                  64

FIGURE 20                HOSPITALS AND DIAGNOSTIC LABORATORIES ACCOUNTED FOR

LARGEST MARKET SHARE IN 2023         65

FIGURE 21                ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING STUDY PERIOD     65

FIGURE 22                IMMUNOHISTOCHEMISTRY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,

AND CHALLENGES  66

FIGURE 23                RATE OF CANCER INCIDENCE, BY REGION AND CANCER TYPE (2022)  68

FIGURE 24                SHARE OF PERSONALIZED MEDICINES APPROVED BY FDA (2015–2023)                  75

FIGURE 25                IMMUNOHISTOCHEMISTRY MARKET:

TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS                78

FIGURE 26                AVERAGE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2021–2023             81

FIGURE 27                AVERAGE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY

CONSUMABLES, 2021–2023 82

FIGURE 28                TOTAL NUMBER OF PATENTS GRANTED, 2014–2024           85

FIGURE 29                TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS,

2014–2024             86

FIGURE 30                VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING PHASE     88

FIGURE 31                IMMUNOHISTOCHEMISTRY MARKET: SUPPLY CHAIN ANALYSIS            89

FIGURE 32                IMMUNOHISTOCHEMISTRY MARKET: ECOSYSTEM ANALYSIS                91

FIGURE 33                IMMUNOHISTOCHEMISTRY MARKET: PORTER’S FIVE FORCES ANALYSIS                  94

FIGURE 34                INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IMMUNOHISTOCHEMISTRY PRODUCTS 96

FIGURE 35                KEY BUYING CRITERIA FOR END USERS 97

FIGURE 36                US: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES          99

FIGURE 37                CANADA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 100

FIGURE 38                EUROPE: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES 101

FIGURE 39                JAPAN: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES    102

FIGURE 40                INDIA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES     104

FIGURE 41                BRAZIL: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES  105

FIGURE 42                IMMUNOHISTOCHEMISTRY MARKET: IMPACT OF AI/GEN AI  108

FIGURE 43                NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT (2023)                  230

FIGURE 44                ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT (2023) 275

FIGURE 45                REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET (2021–2023)          353

FIGURE 46                MARKET SHARE ANALYSIS OF KEY PLAYERS IN

IMMUNOHISTOCHEMISTRY MARKET (2023)          354

FIGURE 47                IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2023              357

FIGURE 48                IMMUNOHISTOCHEMISTRY MARKET: COMPANY FOOTPRINT 358

FIGURE 49                IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023       363

FIGURE 50                PRICE-TO-EARNINGS(P/E) RATIO OF KEY VENDORS                366

FIGURE 51                YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF

KEY VENDORS         366

FIGURE 52                IMMUNOHISTOCHEMISTRY MARKET: BRAND/COMPARISON 367

FIGURE 53                F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)                373

FIGURE 54                DANAHER CORPORATION: COMPANY SNAPSHOT (2023)       382

FIGURE 55                AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)               389

FIGURE 56                PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2023)              397

FIGURE 57                THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2023)         405

FIGURE 58                MERCK KGAA: COMPANY SNAPSHOT (2023)         410

FIGURE 59                BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)                418

FIGURE 60                BIO-TECHNE: COMPANY SNAPSHOT (2023)            423

FIGURE 61                BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)    428

FIGURE 62                TAKARA BIO INC.: COMPANY SNAPSHOT (2023)    434

FIGURE 63                ENZO BIOCHEM INC.: COMPANY SNAPSHOT (2023)               438

MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• UV安定剤市場 – 2030年までの世界予測 2025-05-16
• 産業用通信市場 – 2030年までの世界予測 2025-05-16
• 経腸栄養装置市場 – 2030年までの世界予測 2025-05-15
• データセンターGPU市場 – 2030年までの世界予測 2025-05-15
• ステンレス鋼シームレスパイプ市場 – 2030年までの世界予測 2025-05-15

MarketsandMarkets  出版レポート一覧